España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
David Amsellem
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential
Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock
Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential
Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock
Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug
Piper Jaffray Staying Bullish On Mallinckrodt
Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug
Piper Jaffray Staying Bullish On Mallinckrodt
Piper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros
Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December
Read More...
David Amsellem Recent News
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
Piper Jaffray Downgrades Allergan, Slashes Target To $238
Amsellem: Valeant Has No Floor
Valeant's Calls To Analysts 'Raise Disclosure Questions'
UPDATE: Piper Jaffray Upgrades Forest Laboratories, Previous Thesis is No Longer Tenable
UPDATE: Piper Jaffray Initiates Coverage on Discovery Laboratories on Emerging Respiratory Franchise at Breathtaking Value
UPDATE: Piper Jaffray Downgrades Santarus Following Salix Acquisition Announcement
UPDATE: Piper Jaffray Upgrades Endo Health Solutions as Paladin Transaction is a Game-Changer
UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss
UPDATE: Piper Jaffray Upgrades Questcor Pharmaceuticals Following Strong 2Q13 Report
UPDATE: Piper Jaffray Lowers PT on Allergan Following FDA Draft Guidance
UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue Gaining Traction
UPDATE: Piper Jaffray Initiates The Medicines Company at Overweight on Diverse Medical Portfolio
UPDATE: Piper Jaffray Raises PT on Actavis on Pro Forma Estimates
Salix Pharmaceuticals (SLXP) Gets Overweight From Piper Jaffray
Impax Weakness Overblown, Cash Still Flowing; Piper Jaffray (IPXL)
Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating